Our current and future work, investigating the beneficial and detrimental effects of ICS on lung defense mechanisms, could lead to more appropriate and targeted ICS use in COPD, and spur development of more selective corticosteroids or non-steroidal glucocorticoid receptor agonists. Here, NR3C1 is linked to chronic obstructive pulmonary disease.